Loading organizations...
Transhuman Capital operates as a venture capital firm, investing in therapeutics and related medical technologies. The firm partners with seed through crossover-stage biotechnology companies, focusing on innovations poised to fundamentally improve human health. It specializes in deploying capital into hard science ventures designed to solve significant medical challenges.
The firm's genesis stems from the insight that substantial capital is vital for translating pioneering scientific research into impactful medical solutions. Recognizing advanced therapeutics and technologies can redefine human well-being, it bridges scientific innovation with commercialization, backing ventures extending human potential.
Transhuman Capital supports emerging biotechnology and medical technology companies by providing crucial funding. The firm envisions a future where scientific and technological breakthroughs enhance the human condition, guiding its investment strategy toward transformative medical advancements. It fosters technologies addressing humanity's most pressing health concerns.
Transhuman Capital has 3 tracked investments across 2 companies. The latest tracked deal is $125.0M Series A in Ambros Therapeutics in December 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 16, 2025 | Ambros Therapeutics | $125.0M Series A | Trit Garg, Matthew Hammond | Massimo DI Martino, Adage Capital Management, Arkin BIO Ventures, Balyasny Asset Management, Janus Henderson Investors |
| May 16, 2022 | Kriya Therapeutics | $270.0M Series C | JIM Momtazee | Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT |
| Jul 14, 2021 | Kriya Therapeutics | $100.0M Series B | JIM Momtazee | Alumni Ventures, Amplo, Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, Hongkou, JDRF, Narya Capital, QVT, Woodline Partners |
